fampridine (Rx)

Brand and Other Names:Neurelan
  • Print

Dosing & Uses

AdultPediatricGeriatric

Multiple Sclerosis (Orphan)

Data limited

Fampridine-SR: 10 mg PO q12hr

Spinal Cord Injury (Orphan)

Data limited

9-15 mg/hr continuous IV infusion for ~2 hr, OR

24 mg total cumulative dose, administered as 2 mg IV q20min (Slow IV push or continuous infusion)

Orphan indication sponsor

  • Acorda Therapeutics, Inc; 15 Skyline Dr; Hawthorne, NY 10532

Renal Impairment

90% excreted unchanged

Decrease dose (specific guidelines unavailable)

Safety/efficacy not established

Multiple Sclerosis (Orphan)

Data limited

Fampridine-SR: 10 mg PO q12hr

Spinal Cord Injury (Orphan)

9-15 mg/hr continuous IV infusion for ~2 hr, OR

24 mg total cumulative dose, administered as 2 mg IV q20min (Slow IV push or continuous infusion)

Next:

Adverse Effects

Frequency Not Defined

Seizures (dose-dependent)

Acute confusional episodes

Anxiety

Agitation

Restlessness

Asthenia

Back pain

Paresthesia

Dizziness

Gait instability

Insomnia

Diaphoresis

Inj site pain

Nausea, vomiting

Xerostomia

Abd pain

Incr mean arterial pressure

Previous
Next:

Warnings

Contraindications

Hypersensitivity to fampridine or 3,4-diaminopyridine

History of seizures

Cautions

Avoid pregnancy

Hypertension, arrhythmias, cardiac conduction defects

Renal impairment

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: effects during pregnancy not known, avoid pregnancy

Lactation: not known whether distributed in breast milk, do not nurse

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

Potassium channel blocker; incr CNS and neuromuscular junction acetylcholine release; possibly restores conduction in central demyelinated axons

Pharmacokinetics

Half-Life: 3 hr (PO), 3.5 hr (IV)

Bioavailability: 95%

Peak Plasma Time: 2 min (IV); 3-4 hr (PO)

Protein Binding: Negligible

Vd: 2.6 L/kg

Metabolism: Not metabolized to significant extent

Excretion: Urine (90%)

Previous
Next:

Administration

IV Preparation

Dilute in dextrose/saline (concentration unspecified)

IV Administration (Data limited)

9-15 mg/hr via continuous IV infusion for ~2 hr

24 mg administered in segments by either 2 mg IV q20min (2 mg/30 sec) or 2 mg IV infused over 20 min

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous